Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-04-19
2011-04-19
Kolker, Daniel E (Department: 1649)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388150, C530S809000
Reexamination Certificate
active
07928203
ABSTRACT:
Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
REFERENCES:
patent: 5624821 (1997-04-01), Winter et al.
patent: 6375949 (2002-04-01), Hirano et al.
patent: 6875434 (2005-04-01), Schenk
patent: 6890535 (2005-05-01), Schenk
patent: 6913745 (2005-07-01), Schenk
patent: 6923964 (2005-08-01), Schenk
patent: 6936246 (2005-08-01), Schenk
patent: 7244764 (2007-07-01), Kong et al.
patent: 2004/0223912 (2004-11-01), Montalto et al.
patent: 2006/0280743 (2006-12-01), Basi et al.
patent: 2007/0003552 (2007-01-01), Gebbink et al.
patent: 2007/0178504 (2007-08-01), Colpitts et al.
patent: 0872558 (1998-10-01), None
patent: 95/30642 (1995-11-01), None
patent: 95/35503 (1995-12-01), None
patent: WO 97/04317 (1997-02-01), None
patent: 98/23635 (1998-06-01), None
patent: 01/77167 (2001-10-01), None
Anderson et al., “Cutting edge: biasing immune responses by directing antigen to macrophage Fc gamma receptors,”J. Immunol.168(8):3697-3701 (2002).
Axelrad et al., “Further characterization of amyloid-enhancing factor,”Lab Invest., 47(2):139-146 (1982).
Bard et al., “Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease,”Nat. Med., 6(8):916-919 (2000).
Cevc et al., “Ultraflexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin,”Biochem. Biophys. Acta., 1368(2): 201-215 (1998).
Chicz et al., “Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles,”J. Exp. Med., 178:27-47 (1993).
Clayton et al., “The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease,”Trends Neurosci., 21(6):249-254 (1998).
Cunnane et al., “Amyloid precursors and amyloidosis in rheumatoid arthritis,”Baillieres Best Pract. Res. Clin. Rheumatol., 13(4):615-28 (1999).
de Beer et al., “Identification of a novel serum amyloid A protein in BALB/c mice,”Biochem J., 280(Pt 1):45-49 (1991).
de Beer et al., “Structure of the mouse Saa4 gene and its linkage to the serum amyloid A gene family,”Genomics, 34(1):139-142 (1996).
Falk et al., “Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules,”Immunogenetics, 39(4):230-42 (1994).
Fykse et al., “The primary structure of the variable region of an immunoglobin IV light-chain amyloid-fibril protein (AL GIL),”Biochem. J., 256(2):973-980 (1988).
Giannini et al.,“The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197,”Nucleic Acids Res., 12(10):4063-4069 (1984).
Gillmore et al., “Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein,”Lancet, 358:24-29 (2001).
Glas et al., “Analysis of rearranged immunoglobulin heavy chain variable region genes obtained from a bone marrow transplant (BMT) recipient,”Clin. Exp. Immunol., 107(2):372-380 (1997).
Glenn et al., “Skin immunization made possible by cholera toxin,”Nature, 391(6670):851 (1998).
Hammer et al., “Promiscuous and allele-specific anchors in HLA-DR-binding peptides,”Cell, 74(3):197-203 (1993).
Hanes, “New advances in microsphere-based single-dose vaccines,”Advanced Drug Delivery Reviews, 28(1):97-119 (1997).
Hoffman et al., “Murine tissue amyloid protein AA. NH2-terminal sequence identity with only one of two serum amyloid protein (ApoSAA) gene products.”J. Exp. Med.159:641-646 (1984).
Husby et al., “Interaction between circulating amyloid fibril protein precursors and extracellular tissue matrix components in the pathogenesis of systemic amyloidosis,”Clin. Immunol. lmmunopathol., 70(1):2-9 (1994).
Husby et al., “Serum amyloid A (SAA): Biochemistry, genetics and the pathogenesis of AA amyloidosis,”Amyloid, 1(2):119-137 (1994).
Kisilevsky et al., “Pathogenesis of amyloidosis,”Baillieres Clin. Rheumatol., 8(3):613-626 (1994).
Langer, New methods of drug delivery,Science, 249(4976):1527-1533 (1990).
Ludlage et al., “Systemic AA Amyloidosis in the Common Marmoset,”Vet. Pathol.42:117-124 (2005).
Lundmark et al., “Transmissibility of systemic amyloidosis by a prion-like mechanism,”Proc. Nat. Acad. Sci., 99: 6979-6984 (2002).
Malle et al., “Mapping of antigenic determinants of purified, lipid-free human serum amyloid A proteins,”Scand. J. Immunol., 48:557-561 (1998).
Martin et al., “Structural families in loops of homologous proteins: automatic classification, modelling and application to antibodies,”J. Mol. Biol., 263(5):800-815 (1996).
Paul et al., “Transdermal immunization with large proteins by means of ultradeformable drug carriers,”Eur. J. Immunol.25(12):3521-3524 (1995).
Pepys et al., “Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure,”Proc. Natl. Acad. Sci. U.S.A., 91(12):5602-5606 (1994).
Pras et al., “The characterization of soluble amyloid prepared in water,”J. Clin. Invest., 47(4):924-933 (1968).
Schenk et al., “Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse,”Nature, 400(6740):173-177 (1999).
Sellar et al., “The human serum amyloid A protein (SAA) superfamily gene cluster: mapping to chromosome 11p15.1 by physical and genetic linkage analysis,”Genomics19(2):221-227 (1994).
Senior, “Dosing in phase II trial of Alzheimer's vaccine suspended,”Lancet Neurol.1(1):3 (2002).
Shirai et al., “H3-rules: identification of CDR-H3 structures in antibodies,”FEBS Lett., 455(1-2):188-97 (1999).
Shiroo et al., “Specific deposition of serum amyloid A protein 2 in the mouse,”Scand J. Immunol.26(6):709-716 (1987).
Sinigaglia et al., “A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules,”Nature, 336(6201):778-780 (1988).
Skinner et al., “Murine amyloid protein AA in casein-induced experimental amyloidosis,”Lab Invest.36(4):420-427 (1977).
Solomon et al., “Transgenic mouse model of AA amyloidosis,”Am. J. Pathol.154(4):1267-1272 (1999).
Southwood et al., “Several common HLA-DR types share largely overlapping peptide binding repertoires,”J. Immunology, 160(7):3363-3373 (1998).
Stearman et al., “The sequence and structure of a new serum amyloid A gene,”Nucleic Acids Research, 14(2)797-809 (1986).
Tan et al., “Amyloidosis,”Histopathology. 25(5):403-14 (1994).
Turnell et al., “Secondary structure prediction of human SAA1. Presumptive identification of calcium and lipid binding sites,”Mol. Biol. Med.3(5):387-407 (1986).
Wall et al., “Quantitative high-resolution microradiographic imaging of amyloid deposits in a novel murine model of AA amyloidosis.”Amyloid12(3):149-156 (2005).
Westermark, “The N-terminal segment of protein AA determines its fibrillogenic property,”Biochem. Biophys. Res. Commun.182(1):27-33 (1992).
Yamamoto et al., “Complete primary structures of two major murine serum amyloid A proteins deduced from cDNA sequences,”Proc. Natl. Acad. Sci. U.S.A., 82(9):2915-2919 (1985).
Saldanha José W.
Schenk Dale B.
Seubert Peter A.
Wall Jonathan
Elan Pharmaceuticals Inc.
Kolker Daniel E
University of Tennessee Research Foundation
Womble Carlyle Sandridge & Rice PLLC
LandOfFree
Chimeric, humanized, or human antibody 2A4 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric, humanized, or human antibody 2A4, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric, humanized, or human antibody 2A4 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2668585